Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
CONCLUSION: Our findings suggest a potential consideration for repurposing anti-diabetic weight loss-inducing drugs including semaglutide, dulaglutide, and liraglutide (glucagon-like peptide-1 receptor agonists), empagliflozin (sodium-glucose cotransporter-2 inhibitor), and metformin (biguanide), for MS. This warrants validation through rigorous methodologies and prospective studies.PMID:38566910 | PMC:PMC10986166 | DOI:10.1177/17562864241241383
Source: Adv Data - Category: Epidemiology Authors: Afsaneh Shirani Anne H Cross Olaf Stuve Source Type: research
More News: Adipex | Amphetamine | Brain | Bupropion | Databases & Libraries | Diabetes | Drugs & Pharmacology | Eating Disorders & Weight Management | Empagliflozin | Endocrinology | Epidemiology | Fortamet | Jardiance | Metformin | Multiple Sclerosis | Neurology | Obesity | Phentermine | Profits and Losses | Sodium | Study | Topamax | Victoza | Weight Loss | Wellbutrin